NICE recommends Ipsen drug for medullary thyroid cancer
Ipsen’s (Euronext: IPSEN) good day has got even better with news that the National Institute for Health and Care Excellence (NICE) has recommended Cometriq (cabozantinib) for reimbursement via the National Health Service (NHS) in England and Wales.
The French drugmaker presented a set of financial results that exceeded expectations on Thursday, sending its share price soaring by 10% in morning trading, and bosses will also be pleased by the NICE’s recommendation of Cometriq for patients with medullary thyroid cancer (MTC).
The NICE’s recommendation of the treatment follows negotiations with Ipsen. Cometriq had previously been available via the Cancer Drugs Fund, and under the new-look NICE appraisal system, successfully demonstrated cost-effectiveness to the NHS and clinical value in a real-world setting.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze